Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

FDA Will Review Need For New Laws On Drug Promotion

This article was originally published in The Pink Sheet Daily

Executive Summary

Strategic risk communications plan notes that agency will assess need for "additional legislation or regulation."

You may also be interested in...



Who Will Lead FDA In The Future? Succession Plan Is Not Enough, GAO Says

In its latest report card on FDA, the Government Accountability Office examines the agency's management of such challenges as recruiting and retaining its workforce and communicating with the public

Who Will Lead FDA In The Future? Succession Plan Is Not Enough, GAO Says

In its latest report card on FDA, the Government Accountability Office examines the agency's management of such challenges as recruiting and retaining its workforce and communicating with the public

DDMAC 2.0: FDA To Host November Meeting On Web And New Media Promotion

Advertising rules for search engines, YouTube and blogs are among the topics for the two-day meeting.

Topics

UsernamePublicRestriction

Register

PS122308

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel